Rocket Pharmaceuticals Future Growth
Future criteria checks 2/6
Rocket Pharmaceuticals is forecast to grow earnings and revenue by 57.3% and 52.8% per annum respectively. EPS is expected to grow by 58.7% per annum. Return on equity is forecast to be -35.4% in 3 years.
Key information
57.3%
Earnings growth rate
58.7%
EPS growth rate
Biotechs earnings growth | 24.4% |
Revenue growth rate | 52.8% |
Future return on equity | -35.4% |
Analyst coverage | Good |
Last updated | 03 Jun 2024 |
Recent future growth updates
Recent updates
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Jun 09Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Apr 05Rocket Pharmaceuticals' Promising Path In Gene Therapy
Mar 01Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth
Nov 07Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Oct 03Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate
Aug 25We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Jul 22Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs
Jul 08Rocket Pharma: Poised For Growth In The Rare Disease Space
Jun 30Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside
Jan 30We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Nov 09Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes
Oct 01Rocket earns Evercore nod after positive data for rare genetic disease
Dec 17Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial
Dec 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 484 | -95 | -48 | -67 | 7 |
12/31/2025 | 155 | -219 | -195 | -202 | 12 |
12/31/2024 | 26 | -260 | -224 | -208 | 12 |
3/31/2024 | N/A | -249 | -210 | -194 | N/A |
12/31/2023 | N/A | -246 | -211 | -195 | N/A |
9/30/2023 | N/A | -253 | -236 | -222 | N/A |
6/30/2023 | N/A | -249 | -219 | -208 | N/A |
3/31/2023 | N/A | -237 | -206 | -196 | N/A |
12/31/2022 | N/A | -222 | -186 | -178 | N/A |
9/30/2022 | N/A | -199 | -160 | -153 | N/A |
6/30/2022 | N/A | -192 | -147 | -137 | N/A |
3/31/2022 | N/A | -172 | -145 | -136 | N/A |
12/31/2021 | N/A | -169 | -129 | -121 | N/A |
9/30/2021 | N/A | -186 | -122 | -103 | N/A |
6/30/2021 | N/A | -165 | -108 | -93 | N/A |
3/31/2021 | N/A | -155 | -92 | -77 | N/A |
12/31/2020 | N/A | -140 | -95 | -75 | N/A |
9/30/2020 | N/A | -99 | -98 | -81 | N/A |
6/30/2020 | N/A | -89 | -98 | -75 | N/A |
3/31/2020 | N/A | -82 | -99 | -71 | N/A |
12/31/2019 | N/A | -77 | -88 | -65 | N/A |
9/30/2019 | N/A | -85 | -81 | -66 | N/A |
6/30/2019 | N/A | -82 | -75 | -67 | N/A |
3/31/2019 | N/A | -79 | -60 | -58 | N/A |
12/31/2018 | N/A | -75 | -55 | -54 | N/A |
9/30/2018 | N/A | -54 | -40 | -39 | N/A |
6/30/2018 | N/A | -44 | -32 | -31 | N/A |
3/31/2018 | N/A | -32 | -24 | -24 | N/A |
12/31/2017 | N/A | -20 | N/A | -16 | N/A |
9/30/2017 | N/A | -16 | N/A | -12 | N/A |
6/30/2017 | N/A | -11 | N/A | -9 | N/A |
3/31/2017 | N/A | -9 | N/A | -8 | N/A |
12/31/2016 | N/A | -8 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RCKT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RCKT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RCKT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RCKT's revenue (52.8% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: RCKT's revenue (52.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RCKT is forecast to be unprofitable in 3 years.